Ignite Creation Date:
2024-07-17 @ 10:45 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06489756
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-28
Brief Title:
Highlanders With High Altitude Pulmonary Hypertension HAPH Pulmonary Arterial Pressure PAP Assessed at 3200m With and Without Supplemental Oxygen Therapy SOT
Sponsor:
University of Zurich
Organization:
University of Zurich
Study Overview
Official Title:
Effect of Supplemental Oxygen Therapy SOT on Pulmonary Arterial Pressure in Highlanders With High Altitude Pulmonary Hypertension Permanently Living at 2500m
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension HAPH who permanently live 2500m on pulmonary arterial pressure PAP assessed at 3200 m
Detailed Description:
Highlanders with HAPH diagnosed by echocardiography and defined by a RVRA Tricuspid Regurgitation Pressure Gradient 30 mmHg will be recruited for this project Highlanders permanently living at HA 2500 m will have echocardiografy to assess PAP near their living altitude in Aksay at 3200 m with and without 10Lmin supplemental oxygen therapy SOT via face mask
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None